CMLase strips a 'permanent' glycation scar (CML) from aged human tissue ex vivo

Advanced glycation end-products (AGEs) form when sugars react with long-lived proteins — the same browning chemistry that turns bread to toast — and they accumulate in artery walls, skin, and the lens of the eye over a lifetime. Nε-carboxymethyl-lysine (CML) is the most abundant AGE, and since the 1980s it has been treated as essentially irreversible: a fixed scar of aging. In a paper titled "Reversal of protein chemical aging by enzymatic deglycation" (Nature Communications, 14 Jul 2026), Revel Pharmaceuticals — with collaborators at Calico and the University of Colorado Anschutz Medical Campus — reported an engineered enzyme, CMLase, evolved from a bacterial glycine-oxidase scaffold across more than 500 million variants, that cleaves CML off the protein and restores the native residue. In aged human tissue ex vivo, it reduced CML by more than 70% in arterial tissue from a 75-year-old, more than 55% in skin (below the level typical of 31-year-old skin), and 45–78% in lens proteins.

Why it matters (spine): this is a category flipping from "permanent" to "repairable." Most longevity science slows or measures damage; this removes a specific, well-characterised molecular lesion that the field had written off as un-fixable. It is exactly the kind of verified, source-stamped inflection HKG exists to hold apart from the surrounding hype — a real result, stated at its real (early) scope.

Live status / Provenance: peer-reviewed primary is the Nature Communications paper (DOI 10.1038/s41467-026-75141-2). Announced via a BusinessWire release dated 14 Jul 2026, syndicated across Morningstar, BioSpace, Yahoo Finance and AOL (the redundant paper trail); independent coverage in The Scientist ("lawnmower-like enzyme") and Lifespan.io. Revel CEO Aaron Cravens, on the record: "This class of damage has been seen as a fixed part of aging since the 1980s." Fetched and triangulated in-session on 18 Jul 2026 (post-cutoff item — L4).

Honest scope (the caveat is load-bearing): this is an ex-vivo proof-of-concept on one AGE (CML) in donor tissue under laboratory conditions — not an in-vivo study, not a therapy, and no clinical benefit is claimed. The larger, arguably more damaging crosslink glucosepane is a separate, harder target and was not addressed. What would prove it wrong: independent labs fail to reproduce the CML removal, or the enzymatic chemistry does not translate into safe, functional repair in a living organism.

So we should carry this as HKG's flagship "permanent → repairable" specimen, framed with its scope intact, and use it as the verified answer when the substrate demo asks "can glycation damage be reversed?" — the honest answer is "one AGE, in a dish, yes; in a body, not yet shown." Track the first in-vivo readout, an IND, and any move against glucosepane as the events that would upgrade or break this card.